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Objective: To investigate the toxicity of aqueous extract of Guibourtia tessmannii
(Harms) J. Leonard (G. tessmannii) and evaluate its safety.
Methods: NMRI mice were used to determine the acute toxicity of G. tessmannii.
Increasing concentrations of the plant extracts were administered intraperitoneally or by
force-feeding. General behavior and death were monitored and recorded daily for 7 days.
In order to determine the sub-acute toxicity of the extract, several doses were adminis-
tered by oral gavage daily for 28 days in adult Wistar rats. Different parameters were
assessed including body weight, food and water intake, biochemical parameters and
several vital organ weights.
Results: LD50 of 328.78 mg/kg was obtained by i.p. route and more than 5000 mg/kg
was obtained in acute toxicity by oral route. In sub-acute toxicity, no signiﬁcant alteration
was observed in body weight or vital organs, food and water intake, and biochemical
parameters.
Conclusions: The results showed that the aqueous extract of G. tessmannii has low
toxicity intraperitoneally and no sub-acute toxicity via oral intake.1. Introduction
It is well known that plants are an important source of drugs
worldwide [1–3]. Indeed, over 50% of chemical drugs used forthe treatment of various diseases are derived from vegetables
[4]. In the case of cardiovascular diseases, drugs such as
digitoxin, digoxin, lanatosides A, B, C, are derived from
Digitalis purpurea and Digitalis lanata which are traditionally
used by indigenous people as poison [5]. However, the
traditional usage of plants is not always a guarantee of the
plant safety. In accordance with Ashafa et al. [3], it is
plausible to assume that a history of a plant usage does not
proof its safety.
In Gabon, the use of medicinal plants is claimed to have an
important role in health care system. However, several deaths are
regularly reported by practitioners using traditional medications
due to overdosing. Moreover, in this country, few scientiﬁcarticle under the CC BY-NC-ND license (http://
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eventual side effects of traditional recipes in experiments. Gui-
bourtia tessmannii (Harms) J. Leonard (G. tessmannii) is one of
the most abundantly used medicinal plant in Central Africa for
many purposes such as the treatment of cardiovascular diseases [6–
8], and its aphrodisiac effects in Cameroon [9].
Phytochemical studies performed on G. tessmannii revealed
the presence of bioactive compounds such as tannins, phenolic,
triterpenoids and alkaloids [6,7]. In order to study the biosafety of
this extract in the present study, we determined the acute and
sub-acute toxicity effect of the extract of this plant.
2. Materials and methods
2.1. Plant material
Stem barks of G. tessmannii were collected in the south of
Gabon in August 2010. The plant was authenticated in the
Gabon National Herbarium, the Institute of Pharmacopeia and
Traditional Medicine, Libreville (Gabon) where a voucher
specimen (SRFG 879 LBV) was deposited.
2.2. Aqueous extract
The stem barks of the plant were sun-dried and crushed into
powder using mortar and Culatti micro-crusher. The powder
obtained (1 kg) was macerated in 2000 mL of water during 48 h
at room temperature and ﬁltered using a Whatman millipore
ﬁlter. The ﬁltrate was lyophilized at −40 C. The powder ob-
tained (67.7 g) was stored at 5 C until further use.
2.3. Animals
NMRI mice weighing 19–30 g were used in the acute toxicity
test. Animals were provided by the Health Science Research
Institute (IRSS), Ouagadougou (Burkina Faso). For the sub-
acute toxicity, albino Wistar rats weighing 180–300 g were
used. These animals were provided by the Institute of Pharma-
copoeia and Traditional Medicine, Libreville, Gabon. All ani-
mals were housed under standard laboratory conditions
[(25 ± 1) C] with free access to food and water. Experimental
protocols were carried out and followed the Guide for the Care
and Use of Laboratory Animals of Gabon.
2.4. Acute toxicity tests
The oral acute toxicity test and the intraperitoneal acute
toxicity test were performed. Male and female NMRI mice were
randomly distributed into two control groups and 8 treated
groups with 10 animals in each group. Among the 8 treated
groups, 5 groups of animals were subjected to the intraperitoneal
acute toxicity test (5 males and 5 females), and 3 groups of
animals were subjected to the oral acute toxicity test, in the same
proportions. The two control groups received the water orally or
by i.p. (0.5 mL vehicle). For the oral acute toxicity test, the
treated groups received increasing doses of plant extract (2000,
3000 and 5000 mg/kg weight). Regarding the intraperitoneal
acute toxicity test, increasing doses of the plant extract (150,
250, 300, 500 and 600 mg/kg weight) were administered.
Animals were deprived of food and water overnight prior to
the drug administration. The mice were observed at 0, 30, 60 and120 min after treatment. The animals were observed for
morbidity and mortality once a day, for up to 14 days, with food
and water provided. The number of survivors after 7 days period
was recorded [10–12]. The toxicological effect was assessed on
the basis of mortality, which was expressed as LD50 [13].
2.5. Sub-chronic toxicity
Wistar rats (180–250 g) of both gender were divided into four
groups of 6 animals each (3males and 3 females) andwere housed
under standard conditions and room temperature [(25 ± 1) C].
The control group received the vehicle (0.5 mL) and the
others received increasing oral doses of the plant extract (150,
1500 and 3000 mg/kg weight) by gavage.
Sub-chronic toxicity was evaluated after a single daily
administration of extract per os for a period of 28 days. Animals
were observed daily. Clinical signs, behavioral pattern, food and
water intake, and body weight were monitored. At the end of the
28 days period, animals were deprived of food and water for
15 h and then sacriﬁced for serum biochemical analyses and
organs weighing.
For serum biochemical analyses, blood samples collected
from the heart were dispensed into plain tubes and were
centrifuged at 3500 r/min for 10 min. The serum samples ob-
tained were then used for biochemical parameters analysis such
as: aspartate aminotransferase (AST), alanine aminotransferase
(ALT), alkaline phosphate (ALP), total protein, creatinine, urea,
total cholesterol, using an automated biochemistry analyzer
(Selectra XL Vital Scientiﬁc, Elitech Group Company).
Vital organs such as heart, lungs, liver, kidneys, spleen,
testes, ovary and uterus were carefully dissected, washed with
normal buffer, weighed and examined macroscopically.
2.6. Statistical analysis
Data were expressed as mean ± SEM. They were analyzed by
GraphPad Prism version 5.0 for Windows. Data were assessed by
One-wayANOVAfollowedbyDunnett'smultiple comparison test.
P values less than 0.05 were considered as statistically signiﬁcant.
3. Results
3.1. Acute toxicity study in mice
Oral administration of increasing doses of the aqueous
extract of G. tessmannii (2000, 3000 and 5000 mg/kg) did not
produce any abnormal behavioral responses in male and female
mice during the 14 days of observation. No mortality was
recorded at all dose levels. Orally, the LD50 appeared to
be > 5000 mg/kg.
When administered intraperitoneally, the aqueous extract of
G. tessmannii (150 mg/kg body weight to 600 mg/kg body
weight) showed a LD50 at 328.78 mg/kg body weight. Table 1
summarizes treatment-related responses observed in acute
intraperitoneal toxicity study.
3.2. Sub-chronic toxicity study in rats
3.2.1. Mortality and general behavior
Oral ingestion of the aqueous extract of G. tessmannii
(150 mg/kg body weight to 3000 mg/kg body weight) for 28
Table 2
Sub-chronic toxicity of aqueous extract of G. tessmannii administered by
oral route to rats for 28 days.
Doses (mg/kg) Toxic symptoms
0 None
150 None
1500 Irritability (+), piloerection
3000 Irritability (+++), diarrhea,
piloerection
+: Level of irritability.
Table 3
Effect of aqueous extract of G. tessmannii stem barks on the weight of rats
Doses
(mg/kg)
Day 0 Day 7 D
Males Females Males Females Males
0 181.00 ± 2.08 159.67 ± 5.45 196.67 ± 7.51 178.67 ± 10.03 231.33 ± 12.8
150 146.33 ± 6.56 190.67 ± 10.33 201.00 ± 12.71 162.33 ± 10.72 223.00 ± 7.63
1500 176.67 ± 14.44 205.00 ± 15.88 203.33 ± 9.33 211.00 ± 9.50 211.67 ± 696
3000 222.00 ± 9.00 183.33 ± 16.67 224.00 ± 9.00 190.33 ± 15.89 247.00 ± 4.58
Table 4
The biochemical parameters of male and female rats orally administered the
Gender Parameters Control
Male AST (IU/L) 196.00 ± 5.60
ALT (IU/L) 55.45 ± 3.80
ALP (IU/L) 492.85 ± 2.36
Cholesterol (mmol/L) 1.90 ± 0.10
Urea (mmol/L) 9.50 ± 0.30
Glucose (mmol/L) 5.70 ± 1.06
Total protein (g/L) 57.70 ± 0.40
Creatinine (mmol/L) 92.10 ± 0.32
Female AST (IU/L) 199.80 ± 8.30
ALT (IU/L) 61.50 ± 9.15
ALP (IU/L) 241.15 ± 5.05
Cholesterol (mmol/L) 1.85 ± 0.05
Urea (mmol/L) 9.25 ± 0.25
Glucose (mmol/L) 3.00 ± 0.50
Total protein (g/L) 55.80 ± 0.30
Creatinine (mmol/L) 84.60 ± 4.40
Values are mean ± SEM (n = 3). ANOVA with Dunnett tests showed a: P
Table 1
Acute toxicity of aqueous extract of G. tessmannii stem barks, admin-
istered by the oral or intraperitoneal route to mice.
Route Dose
(mg/kg)
Mortality
(%)
Toxic symptoms
Oral 0 0.00 None
2000 0.00 None
3000 0.00 None
5000 0.00 None
Intraperitoneal 0 0.00 Abdominal contraction
150 3.00 Abdominal contraction
250 16.67 Abdominal contraction, catatonia
300 50.00 Abdominal contraction, catatonia
500 66.67 Abdominal contraction,
catatonia, tachypnea, sedation
600 98.40 Abdominal contraction,
catatonia, tachypnea, sedation
Mice were observed daily for signs of toxicity for 14 days.
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signiﬁcant difference in food and water intake was recorded in
treated and control groups (Table 2). However, abnormal be-
haviors, such as irritability, diarrhea and piloerection were
observed at the 3rd week of the treatment when compared to the
control group.
3.2.2. Body weight alteration in rats
Regarding the body weight, the plant extract (150–3000 mg/
kg) did not induce any signiﬁcant change in the body weight
both in males and females (Table 3).
3.2.3. Biochemical analyses
Table 4 shows the effects of G. tessmannii on biochem-
ical parameters of the serum of rats. A signiﬁcant decrease
in AST (P < 0.05 at 3000 mg/kg) and glucose (P < 0.01 at
150 mg/kg and 1500 mg/kg) was observed in treated rats.
Whereas, no signiﬁcant change in serum concentration of
ALT, ALP, cholesterol, urea, total protein and creatinine was
induced by increasing dose of G. tessmannii in both male
and female rats.
3.2.4. Effect of G. tessmannii on the weight of body
organs
Table 5 shows the effect of G. tessmannii on the weight of
body organs during 28 days. No signiﬁcant change in vital or-
gans weight was induced by the oral administration of increasing
doses of G. tessmannii (150–3000 mg/kg).during 28 days. mg.
ay 14 Day 21 Day 28
Females Males Females Males Females
6 198.67 ± 2.96 223.33 ± 17.16 228.33 ± 6.00 240.67 ± 11.68 230.33 ± 5.17
182.67 ± 6.36 241.33 ± 10.97 196.67 ± 5.45 239.67 ± 8.25 190.00 ± 4.00
202.50 ± 12.50 255.00 ± 8.08 219.50 ± 10.50 241.33 ± 14.94 221.50 ± 12.50
202.67 ± 16.33 258.67 ± 9.28 230.67 ± 18.34 257.67 ± 7.53 232.33 ± 17.02
aqueous extract of G. tessmannii stem barks for 28 days.
Aqueous extract of G. tessmannii (mg/kg)
150 1500 3000
139.97 ± 4.48a 132.2 ± 3.30a 107.00 ± 2.10a
51.50 ± 5.55 46.57 ± 0.84 51.95 ± 4.05
386.40 ± 7.34a 341.20 ± 9.36a 355.5 ± 6.5a
1.70 ± 0.10 1.90 ± 0.17 2.25 ± 0.05
7.97 ± 0.43 8.23 ± 0.86 8.25 ± 0.15
3.57 ± 0.67b 3.07 ± 0.57b 2.23 ± 1.45b
54.47 ± 2.87 57.30 ± 1.05 61.50 ± 2.00
90.43 ± 8.66 91.47 ± 4.14 93.00 ± 3.20
172.80 ± 4.90 135.35 ± 6.05a 123.85 ± 4.85a
62.00 ± 5.78 51.55 ± 6.65 57.13 ± 1.13
263.90 ± 5.73 243.90 ± 9.03 245.20 ± 4.40
1.90 ± 0.15 1.95 ± 0.15 2.00 ± 0.11
9.17 ± 0.76 10.20 ± 0.50 8.55 ± 0.15
2.60 ± 0.45b 1.30 ± 0.30b 1.20 ± 0.30b
62.13 ± 3.87 62.80 ± 4.30 66.85 ± 3.35
88.43 ± 5.89 99.95 ± 2.55 98.80 ± 1.40
< 0.05; b: P < 0.01 compared with control group.
Table 5
Organ weights of male and female rats orally administered the aqueous extract of G. tessmannii stem barks for 28 days. g.
Gender Organs Control Aqueous extract of G. tessmannii (mg/kg)
150 1500 3000
Male Heart 0.37 ± 0.01 0.30 ± 0.02 0.33 ± 0.01 0.38 ± 0.02
Lungs 0.67 ± 0.06 0.79 ± 0.03 0.62 ± 0.02 0.71 ± 0.03
Liver 2.76 ± 0.16 2.64 ± 0.06 2.46 ± 0.13 2.70 ± 0.09
Kidneys Left 0.30 ± 0.00 0.31 ± 0.01 0.30 ± 0.01 0.32 ± 0.00
Right 0.33 ± 0.00 0.32 ± 0.00 0.31 ± 0.01 0.33 ± 0.01
Spleen 0.26 ± 0.02 0.21 ± 0.01 0.25 ± 0.03 0.23 ± 0.02
Testis 1.15 ± 0.15 1.38 ± 0.02 1.18 ± 0.03 1.27 ± 0.09
Female Heart 0.37 ± 0.00 0.41 ± 0.03 0.34 ± 0.01 0.37 ± 0.03
Lungs 0.86 ± 0.01 0.77 ± 0.07 0.99 ± 0.12 0.93 ± 0.16
Liver 2.85 ± 0.01 2.74 ± 0.22 2.63 ± 0.02 2.72 ± 0.16
Kidneys Left 0.31 ± 0.00 0.33 ± 0.01 0.32 ± 0.02 0.35 ± 0.01
Right 0.32 ± 0.01 0.35 ± 0.01 0.31 ± 0.01 0.34 ± 0.01
Spleen 0.28 ± 0.01 0.29 ± 0.01 0.27 ± 0.02 0.25 ± 0.01
Ovary and uterus 0.54 ± 0.02 0.64 ± 0.09 0.43 ± 0.05 0.44 ± 0.01
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The results of the present acute toxicity study indicated,
under our experimental conditions, a wide safety range of
aqueous extract concentrations of G. tessmannii stem barks.
This plant extract at 1000–5000 mg/kg in oral administration
exhibited an oral LD50 value above 5000 mg/kg and did not
induce any mortality. Indeed, based on LD50 value and ac-
cording to the classiﬁcation of Oue´draogo et al. [14], the
chemical labeling and classiﬁcation of acute systemic
toxicity from Organization for Economic Cooperation and
Development [15] and from World Health Organization [16],
the plant extract could be assigned as a Class 5 drug and
then, recognized as low toxic product. This statement was
strengthened by the results obtained in intraperitoneal
administration. Furthermore, we observed quickly reversible
signs of toxicity, and a LD50 estimated at 328.78 mg/kg
which suggest a low toxicity of the plant extract according
to the classiﬁcation of Mezui et al. [17]. The difference
observed between the LD50 values of the oral and
intraperitoneal routes may be explained by the low
bioavailability of the components that might cause toxicity,
the poor absorption from the gastrointestinal tract, or as a
result of a high ﬁrst-pass effect and rapid metabolism to
non-toxic metabolites [18].
In the sub-acute toxicity study in rats, the aqueous extract of
G. tessmannii (150–3000 mg/kg body weight) did not induce
any change in animal behavior, food and water intake, and vital
organs weight as well as the body weight gain. It is well known
that decrease in body weight gain as well as internal organ
weights is a sensitive index of toxicity after exposure to toxic
substances [14,19]. In fact, increase or decrease in body weight
could be due to adverse effects of drugs [19]. The loss of
appetite caused by stress or physiological adaptation to a
drug's intake leads to the reduction of caloric intake when the
body weight reduces [14] or the body fat accumulation during
body weight gain [20].
On the basis of these results, under the same conditions, it has
been suggested that the aqueous extract of G. tessmannii did not
induce any acute toxicity.
The liver and kidneys are two crucial organs that play a key
role in detoxiﬁcation [21]. The effect of the plant extract was
studied on the serum level of ALT, AST, ALP, which areessential for assessing the hepatic function [22] and on urea
and creatinine levels in the blood which are usually used to
evaluate the kidney function [23]. While a rise of transaminases
reﬂects the liver inﬂammation or damage [24], any rise in
creatinine level suggests damages of nephrons function [25].
Regarding the hepatic function monitoring, the plant extract
did not produce deleterious changes in ALT, AST or ALP levels
since no increase of these parameters was observed, suggesting
no hepatotoxicity effect of this plant extract. However, we
observed a decrease in AST level in both males and females
treated with the plant extract. The ALP level also signiﬁcantly
decreased in the male group, but not in female group receiving
G. tessmannii extract. This result corroborates the ability of the
extract of G. tessmannii to restore functional status of liver [7].
No change in creatinine or urea level was obtained suggest-
ing that the plant extract does not affect the renal function.
Regarding other biochemical parameters such as total
cholesterol and total protein, no signiﬁcant difference was
observed compared to the control group. Whereas, a decrease in
glucose level was recorded indicating a hypoglycemic effect of
the plant extract.
Overall, the aqueous extract of G. tessmannii appeared to be
low or non-toxic. Studies including hematopoietic system and
histology are undertaken to further support the safety of the
herbal medicine from G. tessmannii.
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